Epidermal growth factor receptor variant type III markedly accelerates angiogenesis and tumor growth via inducing c-myc mediated angiopoietin-like 4 expression in malignant glioma

Molecular Cancer

Volumn 12, Issue 1, 2013, Pages

  Katanasaka, Yasufumi ^a,c   Kodera, Yasuo ^a   Kitamura, Yuka ^a   Morimoto, Tatsuya ^c   Tamura, Tomohide ^a   Koizumi, Fumiaki ^a,b  

^a NATIONAL CANCER CENTER HOSPITAL   (Japan)

^b NATIONAL CANCER CENTER RESEARCH INSTITUTE   (Japan)

^c UNIVERSITY OF SHIZUOKA   (Japan)

Author keywords

Angiogenesis; Angiopoietin like 4; c Myc; Epidermal growth factor variant type III; Malignant glioma

Indexed keywords

1,4 DIAMINO 1,4 BIS(2 AMINOPHENYLTHIO) 2,3 DICYANOBUTADIENE; ANGIOPOIETIN; ANGIOPOIETIN LIKE 4; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR VARIANT III; GREEN FLUORESCENT PROTEIN; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE; UNCLASSIFIED DRUG;

ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER GROWTH; CELL GROWTH; CHROMATIN IMMUNOPRECIPITATION; CONTROLLED STUDY; FEMALE; GENE OVEREXPRESSION; GENE SILENCING; GENETIC TRANSFECTION; GENETIC VARIABILITY; GLIOBLASTOMA; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; METABOLIC REGULATION; MICROVASCULATURE; MOUSE; NONHUMAN; ONCOGENE C MYC; PROMOTER REGION; PROTEIN EXPRESSION; PROTEIN FUNCTION; REAL TIME POLYMERASE CHAIN REACTION; RNA INTERFERENCE; SIGNAL TRANSDUCTION; TRANSCRIPTION REGULATION; TUMOR VASCULARIZATION; TUMOR XENOGRAFT; WILD TYPE;

ANGIOPOIETINS; ANIMALS; CAPILLARY PERMEABILITY; CELL LINE, TUMOR; DISEASE MODELS, ANIMAL; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE KNOCKDOWN TECHNIQUES; GLIOBLASTOMA; HUMANS; MICE; NEOVASCULARIZATION, PATHOLOGIC; PROTO-ONCOGENE PROTEINS C-MYC; RECEPTOR, EPIDERMAL GROWTH FACTOR; SIGNAL TRANSDUCTION; TRANSCRIPTION, GENETIC; TRANSPLANTATION, HETEROLOGOUS; TUMOR BURDEN; TUMOR MICROENVIRONMENT;

EID: 84876987044     PISSN: None     EISSN: 14764598     Source Type: Journal    
DOI: 10.1186/1476-4598-12-31     Document Type: Article

References (53)

1. Furnari FB, Fenton T, Bachoo RM, Mukasa A, Stommel JM, Stegh A, Hahn WC, Ligon KL, Louis DN, Brennan C. Malignant astrocytic glioma: genetics, biology, and paths to treatment. Genes Dev 2007, 21:2683-2710. 10.1101/gad.1596707, 17974913.
2. Rong Y, Belozerov VE, Tucker-Burden C, Chen G, Durden DL, Olson JJ, Van Meir EG, Mackman N, Brat DJ. Epidermal growth factor receptor and PTEN modulate tissue factor expression in glioblastoma through JunD/activator protein-1 transcriptional activity. Cancer Res 2009, 69:2540-2549. 10.1158/0008-5472.CAN-08-1547, 2759716, 19276385.
3. Maxwell M, Naber SP, Wolfe HJ, Hedley-Whyte ET, Galanopoulos T, Neville-Golden J, Antoniades HN. Expression of angiogenic growth factor genes in primary human astrocytomas may contribute to their growth and progression. Cancer Res 1991, 51:1345-1351.
4. Kreisl TN, Kim L, Moore K, Duic P, Royce C, Stroud I, Garren N, Mackey M, Butman JA, Camphausen K. Phase II trial of single-agent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma. J Clin Oncol 2009, 27:740-745. 10.1200/JCO.2008.16.3055, 2645088, 19114704.
5. Norden AD, Drappatz J, Wen PY. Antiangiogenic therapies for high-grade glioma. Nat Rev Neurol 2009, 5:610-620. 10.1038/nrneurol.2009.159, 19826401.
6. Endersby R, Baker SJ. PTEN signaling in brain: neuropathology and tumorigenesis. Oncogene 2008, 27:5416-5430. 10.1038/onc.2008.239, 18794877.
7. Sampson JH, Archer GE, Mitchell DA, Heimberger AB, Herndon JE, Lally-Goss D, McGehee-Norman S, Paolino A, Reardon DA, Friedman AH. An epidermal growth factor receptor variant III-targeted vaccine is safe and immunogenic in patients with glioblastoma multiforme. Mol Cancer Ther 2009, 8:2773-2779. 10.1158/1535-7163.MCT-09-0124, 2991139, 19825799.
8. Nicholas MK, Lukas RV, Jafri NF, Faoro L, Salgia R. Epidermal growth factor receptor - mediated signal transduction in the development and therapy of gliomas. Clin Cancer Res 2006, 12:7261-7270. 10.1158/1078-0432.CCR-06-0874, 17189397.
9. Huang PH, Xu AM, White FM. Oncogenic EGFR signaling networks in glioma. Sci Signal 2009, 2:re6. 10.1126/scisignal.287re6, 19738203.
10. Frederick L, Wang XY, Eley G, James CD. Diversity and frequency of epidermal growth factor receptor mutations in human glioblastomas. Cancer Res 2000, 60:1383-1387.
11. Gan HK, Kaye AH, Luwor RB. The EGFRvIII variant in glioblastoma multiforme. J Clin Neurosci 2009, 16:748-754. 10.1016/j.jocn.2008.12.005, 19324552.
12. Aldape KD, Ballman K, Furth A, Buckner JC, Giannini C, Burger PC, Scheithauer BW, Jenkins RB, James CD. Immunohistochemical detection of EGFRvIII in high malignancy grade astrocytomas and evaluation of prognostic significance. J Neuropathol Exp Neurol 2004, 63:700-707.
13. Nishikawa R, Ji XD, Harmon RC, Lazar CS, Gill GN, Cavenee WK, Huang HJ. A mutant epidermal growth factor receptor common in human glioma confers enhanced tumorigenicity. Proc Natl Acad Sci USA 1994, 91:7727-7731. 10.1073/pnas.91.16.7727, 44475, 8052651.
14. Tang CK, Gong XQ, Moscatello DK, Wong AJ, Lippman ME. Epidermal growth factor receptor vIII enhances tumorigenicity in human breast cancer. Cancer Res 2000, 60:3081-3087.
15. Heimberger AB, Hlatky R, Suki D, Yang D, Weinberg J, Gilbert M, Sawaya R, Aldape K. Prognostic effect of epidermal growth factor receptor and EGFRvIII in glioblastoma multiforme patients. Clin Cancer Res 2005, 11:1462-1466. 10.1158/1078-0432.CCR-04-1737, 15746047.
16. Li D, Ji H, Zaghlul S, McNamara K, Liang MC, Shimamura T, Kubo S, Takahashi M, Chirieac LR, Padera RF. Therapeutic anti-EGFR antibody 806 generates responses in murine de novo EGFR mutant-dependent lung carcinomas. J Clin Invest 2007, 117:346-352. 10.1172/JCI30446, 1770949, 17256054.
17. Fukai J, Nishio K, Itakura T, Koizumi F. Antitumor activity of cetuximab against malignant glioma cells overexpressing EGFR deletion mutant variant III. Cancer Sci 2008, 99:2062-2069.
18. Hirata A, Ogawa S, Kometani T, Kuwano T, Naito S, Kuwano M, Ono M. ZD1839 (Iressa) induces antiangiogenic effects through inhibition of epidermal growth factor receptor tyrosine kinase. Cancer Res 2002, 62:2554-2560.
19. Bonavia R, Inda MM, Vandenberg S, Cheng SY, Nagane M, Hadwiger P, Tan P, Sah DW, Cavenee WK, Furnari FB. EGFRvIII promotes glioma angiogenesis and growth through the NF-kappaB, interleukin-8 pathway. Oncogene 2012, 31:4054-4066. 10.1038/onc.2011.563, 22139077.
20. Estrada-Bernal A, Lawler SE, Nowicki MO, Ray Chaudhury A, Van Brocklyn JR. The role of sphingosine kinase-1 in EGFRvIII-regulated growth and survival of glioblastoma cells. J Neurooncol 2011, 102:353-366. 10.1007/s11060-010-0345-z, 3085825, 20938717.
21. Kondo M, Asai T, Katanasaka Y, Sadzuka Y, Tsukada H, Ogino K, Taki T, Baba K, Oku N. Anti-neovascular therapy by liposomal drug targeted to membrane type-1 matrix metalloproteinase. Int J Cancer 2004, 108:301-306. 10.1002/ijc.11526, 14639619.
22. Hoffmann J, Schirner M, Menrad A, Schneider MR. A highly sensitive model for quantification of in vivo tumor angiogenesis induced by alginate-encapsulated tumor cells. Cancer Res 1997, 57:3847-3851.
23. Katanasaka Y, Ida T, Asai T, Shimizu K, Koizumi F, Maeda N, Baba K, Oku N. Antiangiogenic cancer therapy using tumor vasculature-targeted liposomes encapsulating 3-(3,5-dimethyl-1H-pyrrol-2-ylmethylene)-1,3-dihydro-indol-2-one, SU5416. Cancer Lett 2008, 270:260-268. 10.1016/j.canlet.2008.05.009, 18555591.
24. Le Jan S, Amy C, Cazes A, Monnot C, Lamande N, Favier J, Philippe J, Sibony M, Gasc JM, Corvol P, Germain S. Angiopoietin-like 4 is a proangiogenic factor produced during ischemia and in conventional renal cell carcinoma. Am J Pathol 2003, 162:1521-1528. 10.1016/S0002-9440(10)64285-X, 1851201, 12707035.
25. Stapleton CM, Joo JH, Kim YS, Liao G, Panettieri RA, Jetten AM. Induction of ANGPTL4 expression in human airway smooth muscle cells by PMA through activation of PKC and MAPK pathways. Exp Cell Res 2010, 316:507-516. 10.1016/j.yexcr.2009.12.004, 2815125, 20025870.
26. Feldkamp MM, Lala P, Lau N, Roncari L, Guha A. Expression of activated epidermal growth factor receptors, Ras-guanosine triphosphate, and mitogen-activated protein kinase in human glioblastoma multiforme specimens. Neurosurgery 1999, 45:1442-1453. 10.1097/00006123-199912000-00034, 10598712.
27. Shigematsu H, Gazdar AF. Somatic mutations of epidermal growth factor receptor signaling pathway in lung cancers. Int J Cancer 2006, 118:257-262. 10.1002/ijc.21496, 16231326.
28. Ueda S, Basaki Y, Yoshie M, Ogawa K, Sakisaka S, Kuwano M, Ono M. PTEN/Akt signaling through epidermal growth factor receptor is prerequisite for angiogenesis by hepatocellular carcinoma cells that is susceptible to inhibition by gefitinib. Cancer Res 2006, 66:5346-5353. 10.1158/0008-5472.CAN-05-3684, 16707461.
29. Gao SP, Mark KG, Leslie K, Pao W, Motoi N, Gerald WL, Travis WD, Bornmann W, Veach D, Clarkson B, Bromberg JF. Mutations in the EGFR kinase domain mediate STAT3 activation via IL-6 production in human lung adenocarcinomas. J Clin Invest 2007, 117:3846-3856. 10.1172/JCI31871, 2096430, 18060032.
30. Meyer N, Penn LZ. Reflecting on 25 years with MYC. Nat Rev Cancer 2008, 8:976-990. 10.1038/nrc2231, 19029958.
31. Maeda H, Wu J, Sawa T, Matsumura Y, Hori K. Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review. J Control Release 2000, 65:271-284. 10.1016/S0168-3659(99)00248-5, 10699287.
32. Wen PY, Kesari S. Malignant gliomas in adults. N Engl J Med 2008, 359:492-507. 10.1056/NEJMra0708126, 18669428.
33. Wu JL, Abe T, Inoue R, Fujiki M, Kobayashi H. IkappaBalphaM suppresses angiogenesis and tumorigenesis promoted by a constitutively active mutant EGFR in human glioma cells. Neurol Res 2004, 26:785-791. 10.1179/016164104225014139, 15494123.
34. Jain RK, di Tomaso E, Duda DG, Loeffler JS, Sorensen AG, Batchelor TT. Angiogenesis in brain tumours. Nat Rev Neurosci 2007, 8:610-622.
35. Padua D, Zhang XH, Wang Q, Nadal C, Gerald WL, Gomis RR, Massague J. TGFbeta primes breast tumors for lung metastasis seeding through angiopoietin-like 4. Cell 2008, 133:66-77. 10.1016/j.cell.2008.01.046, 2390892, 18394990.
36. Oike Y, Ito Y, Maekawa H, Morisada T, Kubota Y, Akao M, Urano T, Yasunaga K, Suda T. Angiopoietin-related growth factor (AGF) promotes angiogenesis. Blood 2004, 103:3760-3765. 10.1182/blood-2003-04-1272, 14764539.
37. Veliceasa D, Schulze-Hoepfner FT, Volpert OV. PPARgamma and Agonists against Cancer: Rational Design of Complementation Treatments. PPAR Res 2008, 2008:945275. 2586323, 19043603.
38. Tian L, Zhou J, Casimiro MC, Liang B, Ojeifo JO, Wang M, Hyslop T, Wang C, Pestell RG. Activating peroxisome proliferator-activated receptor gamma mutant promotes tumor growth in vivo by enhancing angiogenesis. Cancer Res 2009, 69:9236-9244. 10.1158/0008-5472.CAN-09-2067, 2794957, 19934321.
39. Nakayama T, Hirakawa H, Shibata K, Abe K, Nagayasu T, Taguchi T. Expression of angiopoietin-like 4 in human gastric cancer: ANGPTL4 promotes venous invasion. Oncol Rep 2010, 24:599-606.
40. Shibata K, Nakayama T, Hirakawa H, Hidaka S, Nagayasu T. Clinicopathological significance of angiopoietin-like protein 4 expression in oesophageal squamous cell carcinoma. J Clin Pathol 2010, 63:1054-1058. 10.1136/jcp.2010.078600, 20861003.
41. Hu J, Jham BC, Ma T, Friedman ER, Ferreira L, Wright JM, Accurso B, Allen CM, Basile JR, Montaner S. Angiopoietin-like 4: A novel molecular hallmark in oral Kaposi's sarcoma. Oral Oncol 2011, 47:371-375. 10.1016/j.oraloncology.2011.02.018, 3098933, 21421336.
42. Nakayama T, Hirakawa H, Shibata K, Nazneen A, Abe K, Nagayasu T, Taguchi T. Expression of angiopoietin-like 4 (ANGPTL4) in human colorectal cancer: ANGPTL4 promotes venous invasion and distant metastasis. Oncol Rep 2011, 25:929-935.
43. Kim I, Kim HG, Kim H, Kim HH, Park SK, Uhm CS, Lee ZH, Koh GY. Hepatic expression, synthesis and secretion of a novel fibrinogen/angiopoietin-related protein that prevents endothelial-cell apoptosis. Biochem J 2000, 346:603-610. 10.1042/0264-6021:3460603, 1220891, 10698685.
44. Cazes A, Galaup A, Chomel C, Bignon M, Brechot N, Le Jan S, Weber H, Corvol P, Muller L, Germain S, Monnot C. Extracellular matrix-bound angiopoietin-like 4 inhibits endothelial cell adhesion, migration, and sprouting and alters actin cytoskeleton. Circ Res 2006, 99:1207-1215. 10.1161/01.RES.0000250758.63358.91, 2241731, 17068295.
45. Ma T, Jham BC, Hu J, Friedman ER, Basile JR, Molinolo A, Sodhi A, Montaner S. Viral G protein-coupled receptor up-regulates Angiopoietin-like 4 promoting angiogenesis and vascular permeability in Kaposi's sarcoma. Proc Natl Acad Sci USA 2010, 107:14363-14368. 10.1073/pnas.1001065107, 2922606, 20660728.
46. Hermann LM, Pinkerton M, Jennings K, Yang L, Grom A, Sowders D, Kersten S, Witte DP, Hirsch R, Thornton S. Angiopoietin-like-4 is a potential angiogenic mediator in arthritis. Clin Immunol 2005, 115:93-101. 10.1016/j.clim.2004.12.002, 15870027.
47. Galaup A, Cazes A, Le Jan S, Philippe J, Connault E, Le Coz E, Mekid H, Mir LM, Opolon P, Corvol P. Angiopoietin-like 4 prevents metastasis through inhibition of vascular permeability and tumor cell motility and invasiveness. Proc Natl Acad Sci USA 2006, 103:18721-18726. 10.1073/pnas.0609025103, 1693729, 17130448.
48. Ito Y, Oike Y, Yasunaga K, Hamada K, Miyata K, Matsumoto S, Sugano S, Tanihara H, Masuho Y, Suda T. Inhibition of angiogenesis and vascular leakiness by angiopoietin-related protein 4. Cancer Res 2003, 63:6651-6657.
49. Edwards LA, Verreault M, Thiessen B, Dragowska WH, Hu Y, Yeung JH, Dedhar S, Bally MB. Combined inhibition of the phosphatidylinositol 3-kinase/Akt and Ras/mitogen-activated protein kinase pathways results in synergistic effects in glioblastoma cells. Mol Cancer Ther 2006, 5:645-654. 10.1158/1535-7163.MCT-05-0099, 16546979.
50. Fuse C, Ishida Y, Hikita T, Asai T, Oku N. Junctional adhesion molecule-C promotes metastatic potential of HT1080 human fibrosarcoma. J Biol Chem 2007, 282:8276-8283. 10.1074/jbc.M608836200, 17227766.
51. Koizumi F, Shimoyama T, Taguchi F, Saijo N, Nishio K. Establishment of a human non-small cell lung cancer cell line resistant to gefitinib. Int J Cancer 2005, 116:36-44. 10.1002/ijc.20985, 15761868.
52. Yonezawa S, Asai T, Oku N. Effective tumor regression by anti-neovascular therapy in hypovascular orthotopic pancreatic tumor model. J Control Release 2007, 118:303-309. 10.1016/j.jconrel.2006.12.024, 17275944.
53. Fernandez-Lopez D, Faustino J, Daneman R, Zhou L, Lee SY, Derugin N, Wendland MF, Vexler ZS. Blood-brain barrier permeability is increased after acute adult stroke but not neonatal stroke in the rat. J Neurosci 2012, 32:9588-9600. 10.1523/JNEUROSCI.5977-11.2012, 3539825, 22787045.